Michael A Postow,Richard D Carvajal
Michael A Postow
Melanoma is a heterogeneous disease representing distinct biologic and genetic subsets. Activating mutations in KIT have been discovered in a significant proportion of melanomas arising from acral, mucosal, and chronically sun-damaged sites...
Fergal C Kelleher,Grant A McArthur
Fergal C Kelleher
Cutaneous melanomas have mutations in the NRAS GTPase in 15% of cases. Compared to melanomas with BRAF mutations, or melanomas "wild-type" for BRAF and NRAS, melanomas with NRAS mutations are more likely to be thicker tumors and to have a h...
Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies [0.03%]
黑色素瘤治疗中的靶向药物——BRAF突变抑制剂:现状与前景
Ragini Kudchadkar,Kim H T Paraiso,Keiran S M Smalley
Ragini Kudchadkar
The discovery of activating BRAF mutations in ∼50% of all melanomas has proved to be a turning point in the therapeutic management of the disseminated disease. In this commentary, we review the latest research delineating the role of mutan...
Melissa Ann Wilson,Katherine L Nathanson
Melissa Ann Wilson
Melanoma is the deadliest form of skin cancer and is increasing in incidence. Recent treatment advances have been made, but there remains a need for continued development of effective therapy options, as treatment rarely leads to cure. Many...
Special issue on melanoma [0.03%]
关于黑色素瘤的特刊
Michael A Davies
Michael A Davies
Siyuan Zheng,Milan G Chheda,Roel G W Verhaak
Siyuan Zheng
Glioblastoma multiforme is a histopathologically heterogeneous disease with few treatment options. Therapy based on genomic alterations is rapidly gaining popularity because of the high response rate and high specificity. DNA copy number an...
Glioblastoma cancer stem-like cells: implications for pathogenesis and treatment [0.03%]
胶质母细胞瘤癌干细胞:发病机制和治疗的启示
Edjah Kweku-Ebura Nduom,Costas George Hadjipanayis,Erwin G Van Meir
Edjah Kweku-Ebura Nduom
Glioblastoma remains one of the deadliest forms of cancer. Infiltrating cancer cells in the surrounding brain prevent complete resection, and tumor cell resistance to chemoradiation results in the poor prognosis of the glioblastoma (GBM) pa...
Jiangbing Zhou,Kofi-Buaku Atsina,Benjamin T Himes et al.
Jiangbing Zhou et al.
Brain tumors--particularly glioblastoma multiforme--pose an important public health problem in the United States. Despite surgical and medical advances, the prognosis for patients with malignant gliomas remains grim: current therapy is insu...
Gene and viral therapy for glioblastoma: a review of clinical trials and future directions [0.03%]
胶质母细胞瘤的基因和病毒治疗:临床试验及未来方向综述
Ahmed Mohyeldin,Ennio Antonio Chiocca
Ahmed Mohyeldin
Progress in improving the prognosis of patients with glioblastoma has been modest and has predominantly relied on informative imaging, optimization of medical and surgical treatment, and approval of new drugs with modest benefits on overall...
Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates [0.03%]
胶质母细胞瘤的溶瘤病毒治疗:概念与候选病毒
Guido Wollmann,Koray Ozduman,Anthony N van den Pol
Guido Wollmann
Twenty years of oncolytic virus development have created a field that is driven by the potential promise of lasting impact on our cancer treatment repertoire. With the field constantly expanding-more than 20 viruses have been recognized as ...